SummaryThis is a dose escalation and expansion trial. In the dose escalation phase (Part 1) eligible participants will be allocated to one of three stages. Stage 1 will evaluate escalating doses of CC-95251, administered intravenously (IV), to determine the maximum tolerated dose (MTD), non-tolerated dose (NTD), and/or recommended Phase 2 dose (RP2D). Stage 2 will evaluate escalating doses of CC-95251 in combination with weekly cetuximab, both administered IV, to determine the MTD, NTD, and/or RP2D of CC-95251 plus cetuximab. Stage 3 will evaluate escalating doses of CC-95251 in combination with rituximab, both administered IV, to establish MTD, NTD, and/or RP2D of CC-95251 plus rituximab.
This trial is treating patients with advanced cancers (including some types of blood cancer).
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers